公开(公告)号：US20050026137A1

公开(公告)日：2005-02-03

申请号：US10476615

申请日：2002-05-03

Applicant: Kai Krohn ,  Vesna Blazevic ,  Marja Tahtinen ,  Mart Ustav ,  Urve Toots ,  Andres Mannjk ,  Annamari Ranki ,  Ene Ustav

Inventor： Kai Krohn ,  Vesna Blazevic ,  Marja Tahtinen ,  Mart Ustav ,  Urve Toots ,  Andres Mannjk ,  Annamari Ranki ,  Ene Ustav

IPC: A61K48/00 ,  C12N15/85 ,  C12Q1/70 ,  C12N15/86

CPC classification number: C07K14/005 ,  A61K48/00 ,  A61K2039/53 ,  C12N15/85 ,  C12N2800/108 ,  C12N2830/42 ,  C12N2840/20 ,  C12N2840/203

Abstract: The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing said vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics containing the vectors, and to therapeutic uses of said vectors. More specifically, the present invention relates to novel vectors comprising (a) an expression cassette of a gene of a nuclear-anchoring protein, which contains (i) a DNA binding domain capable of binding to a specific DNA sequence and (ii) a functional domain capable of binding to a nuclear component and (b) a multimerized DNA sequence forming a binding site for the anchoring protein, and optionally (c) one or more expression cassettes of a DNA sequence of interest. In particular the invention relates to vectors that lack a papilloma virus origin of replication. The nuclear-anchoring protein might be the E2 protein of Bovine Papilloma Virus type 1 or Epstein-Barr Virus Nuclear Antigen 1. The invention also relates to vectors that lack an origin of replication functional in a mammalian cell. The invention further relates to methods for expressing a DNA sequence of interest in a subject.

Abstract translation: 本发明涉及新载体，DNA疫苗和含有所述载体的基因治疗剂，用于制备载体和DNA疫苗的方法以及含有载体的基因治疗剂以及所述载体的治疗用途。 更具体地说，本发明涉及包含（a）核锚定蛋白基因的表达盒的新载体，其包含（i）能够结合特定DNA序列的DNA结合结构域和（ii）功能性 能够结合核组分的结构域和（b）形成锚定蛋白的结合位点的多聚化DNA序列，以及任选（c）感兴趣的DNA序列的一个或多个表达盒。 特别地，本发明涉及缺乏乳头瘤病毒复制起点的载体。 核锚定蛋白可能是牛乳头瘤病毒1型或爱泼斯坦 - 巴尔病毒核抗原1的E2蛋白。本发明还涉及在哺乳动物细胞中缺乏复制起点的载体。 本发明还涉及在受试者中表达感兴趣的DNA序列的方法。